DOCSLIB.ORG

Screening for Epigenetic Inhibitors of Osteosarcoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Screening for Epigenetic Inhibitors of Osteosarcoma SCREENING FOR EPIGENETIC INHIBITORS OF OSTEOSARCOMA METASTASIS by IAN BAYLES Submitted in partial fulfillment of requirements for the degree of Doctor of Philosophy Department of Genetics and Genome Sciences CASE WESTERN RESERVE UNIVERSITY May 2020 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Ian Bayles Candidate for the degree of Doctor of Philosophy* Committee chair Ahmad Khalil Committee Member Peter Scacheri Committee Member Edward Greenfield Committee Member Fulai Jin Date of Defense November 22nd, 2019 *We also certify that written approval has been obtained for any proprietary material contained therein. 2 Table of Contents AcKnowledgements .................................................................................................... 7 Abstract ........................................................................................................................ 9 Chapter 1: BacKground and Significance ............................................................ 11 Osteosarcoma................................................................................................................... 11 Osteosarcoma epidemiology ........................................................................................ 11 Classification .................................................................................................................. 12 Localization ..................................................................................................................... 13 Genetic Heterogeneity/Pathogenesis ........................................................................... 13 Therapeutic Strategies for Osteosarcoma ................................................................... 15 Cancer Metastasis............................................................................................................ 17 Genetic evolution of metastasis .................................................................................... 18 Epigenetic contribution to metastasis ........................................................................... 19 Epigenetic targeting compounds in cancer treatment ............................................. 21 Epigenetic Writers .......................................................................................................... 22 Epigenetic Erasers ......................................................................................................... 24 Epigenetic Readers........................................................................................................ 25 CDKs and their Inhibitors .............................................................................................. 26 Chapter 2. Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma ............................................................................................................ 29 Abstract.............................................................................................................................. 30 Introduction ....................................................................................................................... 31 Results ............................................................................................................................... 33 Ex vivo screening identifies CDK inhibitors as potent suppressors of metastatic OS outgrowth ........................................................................................................................ 33 CDK12 inhibitors reduce metastatic cell outgrowth in the lung microenvironment .. 35 CDK12 knockout reduces lung metastatic outgrowth in vivo ..................................... 36 CDK12 inhibition is broadly effective against multiple human OS cell lines in vitro . 37 E9 impairs transcription elongation in OS cells ........................................................... 39 CDK12 inhibition affects transcription elongation and RNA processing in OS cells 42 3 MYC levels correlate with sensitivity to E9 ex vivo. .................................................... 43 Discussion ......................................................................................................................... 44 Methods ............................................................................................................................. 48 Chapter 3: Discussion and Future Directions .................................................. 104 Summary .......................................................................................................................... 104 The effects of the tumor microenvironment in compound screening ................. 107 Using the PuMA technique to study lung metastasis in other cancers .............. 109 CDK Inhibitors in Osteosarcoma and Other Cancers ............................................. 109 CDK12 inhibition as a therapeutic option in osteosarcoma .................................. 112 Combining CDK12 inhibitors with other therapeutic options in cancer ............. 113 Effects of TP53 mutational status on CDK12 inhibition ......................................... 117 Efficacy of CDK12 inhibitors in vivo........................................................................... 118 Effects of CDK12 inhibition in osteosarcoma transcription. ................................. 119 Implications of CDK12 inhibition from CDK12 loss in other cancers .................. 121 Bibliography ............................................................................................................ 125 4 List of Tables Supplemental Table 2-1: Compounds used in Screens…………………………85 Supplemental Table 2-2: Top 100 GSEA terms………………………………….94 5 List of Figures Figure 1-1: Overview of epigenetic inhibitors in cancer treatment. ....................23 Figure 2-1: An ex vivo screen identifies compounds that inhibit the growth of metastatic OS......................................................................................................66 Supplemental Figure 2-1: Parallel in vitro screen data .....................................67 Figure 2-2: CDK inhibitors reduce metastatic cell outgrowth in the lung microenvironment ................................................................................................68 Supplemental Figure 2-2.1: CDK expression across tumor samples ................70 Supplemental Figure 2-2.2: Protein expression of CDK12 after CRISPR knockout ..............................................................................................................71 Figure 2-3: THZ531 and E9 show broad activity against OS cell line models. ...72 Supplemental Figure 2-3: Cell line data after CDK12 inhibitor treatment .........74 Figure 2-4: E9 treatment impairs transcription elongation in OS cells. ...............76 Supplemental Figure 2-4: E9 ChIP-seq in MG63.3 Cells ..................................78 Figure 2-5: E9 affects transcript levels in a gene-length and expression- dependent manner. .............................................................................................79 Supplemental Figure 2-5: E9 impairs transcription in MG63.3 cells ..................81 Figure 2-6: High levels of MYC correlate with insensitivity of OS cells to E9 treatment ex vivo .................................................................................................84 Figure 3-1: Bliss Synergy Score of THZ531 and Olaparib ...Error! BooKmarK not defined. 6 AcKnowledgements I want to start off by thanking Dr. Peter Scacheri, my Ph.D. thesis advisor and mentor. His guidance and wisdom over the last five and half years has helped mold me into the scientist I am today. He reminded me that while science can be tedious and frustrating as experiments inevitably fail, as long as you keep the end goal in mind and celebrate your successes, it will all be worth it in the end. His excitement over every result of data (“This is AWESOME!”) helped drive me to put my all into my work and I couldn’t be more thankful for his support and guidance. I want to thank my wife and partner, the future-doctor Kathleen Plona for all of her help and support and for dealing with me squirreled away in my office staring at my computer screen for nights on end. I truly appreciate her support and cannot wait to begin our future together as scientists. I want to thank you my lab mates for their help and support, especially Zach and Cindy. They are the foundations of the current Scacheri lab and I hope Pete realizes how incredible they are to the graduate students in the lab. I want to thank my committee members, Dr. Ahmad Khalil, Dr. Edward Greenfield, and Dr. Fulai Jin for their help and input over the years, and for helping to guide this thesis to where it is today. 7 I want to thank my family, my mother, father, and sister, for their help and inspiration during this process. I lastly want to thank my fellow BSTP classmates and whiskey drinking partners newly minted doctors, Tristan de Jesus and Douglas Oswald. Thank you for helping to keep me grounded and sane during our respective PhDs and for sharing your science with me. 8 Screening for Epigenetic Inhibitors of Osteosarcoma Metastasis by IAN BAYLES Abstract Osteosarcoma is a the most common cancer of the bone, known for its notoriously complex and heterogeneous genotypes and high propensity to metastasize to the lung. When distal metastatic lesions present in patients, mortality rates increase significantly. Indeed, this is the case
Load more

Recommended publications
  • Histone Deacetylase Inhibitors: an Attractive Therapeutic Strategy Against Breast Cancer
    ANTICANCER RESEARCH 37 : 35-46 (2017) doi:10.21873/anticanres.11286 Review Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer CHRISTOS DAMASKOS 1,2* , SERENA VALSAMI 3* , MICHAEL KONTOS 4* , ELEFTHERIOS SPARTALIS 2, THEODOROS KALAMPOKAS 5, EMMANOUIL KALAMPOKAS 6, ANTONIOS ATHANASIOU 4, DEMETRIOS MORIS 7, AFRODITE DASKALOPOULOU 2,8 , SPYRIDON DAVAKIS 4, GERASIMOS TSOUROUFLIS 1, KONSTANTINOS KONTZOGLOU 1, DESPINA PERREA 2, NIKOLAOS NIKITEAS 2 and DIMITRIOS DIMITROULIS 1 1Second Department of Propedeutic Surgery, 4First Department of Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 2N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 3Blood Transfusion Department, Aretaieion Hospital, Medical School, National and Kapodistrian Athens University, Athens, Greece; 5Assisted Conception Unit, Second Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 6Gynaecological Oncology Department, University of Aberdeen, Aberdeen, U.K.; 7Lerner Research Institute, Cleveland Clinic, Cleveland, OH, U.S.A; 8School of Biology, National and Kapodistrian University of Athens, Athens, Greece Abstract. With a lifetime risk estimated to be one in eight in anticipate further clinical benefits of this new class of drugs, industrialized countries, breast cancer is the most frequent
    [Show full text]
  • Genome‐Wide Association Studies of the Self‐Rating of Effects of Ethanol (SRE)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by eScholarship - University of California UC San Diego UC San Diego Previously Published Works Title Genome-wide association studies of the self-rating of effects of ethanol (SRE). Permalink https://escholarship.org/uc/item/94p1n78c Journal Addiction biology, 25(2) ISSN 1355-6215 Authors Lai, Dongbing Wetherill, Leah Kapoor, Manav et al. Publication Date 2020-03-01 DOI 10.1111/adb.12800 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Received: 18 December 2018 Revised: 6 May 2019 Accepted: 27 May 2019 DOI: 10.1111/adb.12800 ORIGINAL ARTICLE Genome‐wide association studies of the self‐rating of effects of ethanol (SRE) Dongbing Lai1 | Leah Wetherill1 | Manav Kapoor2 | Emma C. Johnson3 | Melanie Schwandt4 | Vijay A. Ramchandani5 | David Goldman4 | Geoff Joslyn6 | Xi Rao1 | Yunlong Liu1 | Sean Farris7 | R. Dayne Mayfield7 | Danielle Dick8 | Victor Hesselbrock9 | John Kramer10 | Vivia V. McCutcheon3 | John Nurnberger1,11 | Jay Tischfield12 | Alison Goate2 | Howard J. Edenberg1,13 | Bernice Porjesz14 | Arpana Agrawal3 | Tatiana Foroud1 | Marc Schuckit15 1 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana 2 Department of Neuroscience, Icahn School of Medicine at Mt. Sinai, New York, New York 3 Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 4 Office of the Clinical Director, National Institute on Alcohol Abuse
    [Show full text]
  • Epigenetic Reprogramming of Tumor-Associated Fibroblasts in Lung Cancer: Therapeutic Opportunities
    cancers Review Epigenetic Reprogramming of Tumor-Associated Fibroblasts in Lung Cancer: Therapeutic Opportunities Jordi Alcaraz 1,2,3,*, Rafael Ikemori 1 , Alejandro Llorente 1 , Natalia Díaz-Valdivia 1 , Noemí Reguart 2,4 and Miguel Vizoso 5,* 1 Unit of Biophysics and Bioengineering, Department of Biomedicine, School of Medicine and Health Sciences, Universitat de Barcelona, 08036 Barcelona, Spain; [email protected] (R.I.); [email protected] (A.L.); [email protected] (N.D.-V.) 2 Thoracic Oncology Unit, Hospital Clinic Barcelona, 08036 Barcelona, Spain; [email protected] 3 Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), 08028 Barcelona, Spain 4 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain 5 Division of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands * Correspondence: [email protected] (J.A.); [email protected] (M.V.) Simple Summary: Lung cancer is the leading cause of cancer death among both men and women, partly due to limited therapy responses. New avenues of knowledge are indicating that lung cancer cells do not form a tumor in isolation but rather obtain essential support from their surrounding host tissue rich in altered fibroblasts. Notably, there is growing evidence that tumor progression and even the current limited responses to therapies could be prevented by rescuing the normal behavior of fibroblasts, which are critical housekeepers of normal tissue function. For this purpose, it is key Citation: Alcaraz, J.; Ikemori, R.; to improve our understanding of the molecular mechanisms driving the pathologic alterations of Llorente, A.; Díaz-Valdivia, N.; fibroblasts in cancer.
    [Show full text]
  • CD29 Identifies IFN-Γ–Producing Human CD8+ T Cells With
    + CD29 identifies IFN-γ–producing human CD8 T cells with an increased cytotoxic potential Benoît P. Nicoleta,b, Aurélie Guislaina,b, Floris P. J. van Alphenc, Raquel Gomez-Eerlandd, Ton N. M. Schumacherd, Maartje van den Biggelaarc,e, and Monika C. Wolkersa,b,1 aDepartment of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; bLandsteiner Laboratory, Oncode Institute, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; cDepartment of Research Facilities, Sanquin Research, 1066 CX Amsterdam, The Netherlands; dDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; and eDepartment of Molecular and Cellular Haemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands Edited by Anjana Rao, La Jolla Institute for Allergy and Immunology, La Jolla, CA, and approved February 12, 2020 (received for review August 12, 2019) Cytotoxic CD8+ T cells can effectively kill target cells by producing therefore developed a protocol that allowed for efficient iso- cytokines, chemokines, and granzymes. Expression of these effector lation of RNA and protein from fluorescence-activated cell molecules is however highly divergent, and tools that identify and sorting (FACS)-sorted fixed T cells after intracellular cytokine + preselect CD8 T cells with a cytotoxic expression profile are lacking. staining. With this top-down approach, we performed an un- + Human CD8 T cells can be divided into IFN-γ– and IL-2–producing biased RNA-sequencing (RNA-seq) and mass spectrometry cells. Unbiased transcriptomics and proteomics analysis on cytokine- γ– – + + (MS) analyses on IFN- and IL-2 producing primary human producing fixed CD8 T cells revealed that IL-2 cells produce helper + + + CD8 Tcells.
    [Show full text]
  • Cyclin-Dependent Kinases and Their Role in Inflammation, Endothelial Cell Migration
    Cyclin-Dependent Kinases and their role in Inflammation, Endothelial Cell Migration and Autocrine Activity Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Shruthi Ratnakar Shetty Graduate Program in Pharmaceutical Sciences The Ohio State University 2020 Dissertation Committee Dale Hoyt, Advisor Liva Rakotondraibe Moray Campbell Keli Hu Copyrighted by Shruthi Ratnakar Shetty 2020 Abstract Inflammation is the body’s response to infection or injury. Endothelial cells are among the different players involved in an inflammatory cascade. In response to an inflammatory stimuli such as bacterial lipopolysaccharide (LPS), endothelial cells get activated which is characterized by the production of important mediators, such as inducible nitric oxide synthase (iNOS) which, catalyzes the production of nitric oxide (NO) and reactive nitrogen species and cyclooxygenase-2 (COX-2) that catalyzes the production of prostaglandins. Though the production of these mediators is required for an inflammatory response, it is important that their levels are regulated. Continued production of iNOS results in increased accumulation of reactive nitrogen species (RNS) that might lead to cytotoxicity, whereas lack of/suppression results in endothelial and vascular dysfunction. On the other hand, severe cardiovascular, intestinal and renal side effects are observed with significant suppression of COX-2. Thus, studying factors that could regulate the levels of iNOS and COX-2 could provide useful insights for developing novel therapeutic targets. Regulation of protein levels involves control of protein induction or turnover. Since protein induction requires transcription, in this dissertation we studied the role of a promoter of transcription “Cyclin- dependent kinase 7 (CDK7)” in iNOS and COX-2 protein induction.
    [Show full text]
  • Targeting Cyclin-Dependent Kinase 9 and Myeloid Cell Leukaemia 1 in MYC-Driven B-Cell Lymphoma
    Targeting cyclin-dependent kinase 9 and myeloid cell leukaemia 1 in MYC-driven B-cell lymphoma Gareth Peter Gregory ORCID ID: 0000-0002-4170-0682 Thesis for Doctor of Philosophy September 2016 Sir Peter MacCallum Department of Oncology The University of Melbourne Doctor of Philosophy Submitted in total fulfilment of the degree of Abstract Aggressive B-cell lymphomas include diffuse large B-cell lymphoma, Burkitt lymphoma and intermediate forms. Despite high response rates to conventional immuno-chemotherapeutic approaches, an unmet need for novel therapeutic by resistance to chemotherapy and radiotherapy. The proto-oncogene MYC is strategies is required in the setting of relapsed and refractory disease, typified frequently dysregulated in the aggressive B-cell lymphomas, however, it has proven an elusive direct therapeutic target. MYC-dysregulated disease maintains a ‘transcriptionally-addicted’ state, whereby perturbation of A significant body of evidence is accumulating to suggest that RNA polymerase II activity may indirectly antagonise MYC activity. Furthermore, very recent studies implicate anti-apoptotic myeloid cell leukaemia 1 (MCL-1) as a critical survival determinant of MYC-driven lymphoma. This thesis utilises pharmacologic and genetic techniques in MYC-driven models of aggressive B-cell lymphoma to demonstrate that cyclin-dependent kinase 9 (CDK9) and MCL-1 are oncogenic dependencies of this subset of disease. The cyclin-dependent kinase inhibitor, dinaciclib, and more selective CDK9 inhibitors downregulation of MCL1 are used
    [Show full text]
  • PRMT3 (1-531, His-Tag) Human Protein – AR51778PU-N | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for AR51778PU-N PRMT3 (1-531, His-tag) Human Protein Product data: Product Type: Recombinant Proteins Description: PRMT3 (1-531, His-tag) human recombinant protein, 0.5 mg Species: Human Expression Host: E. coli Tag: His-tag Predicted MW: 62.3 kDa Concentration: lot specific Purity: >90% by SDS - PAGE Buffer: Presentation State: Purified State: Liquid purified protein Buffer System: Phosphate buffer saline (pH 7.4) containing 20% glycerol, 1mM DTT. Preparation: Liquid purified protein Protein Description: Recombinant human PRMT3, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography techniques. Storage: Store undiluted at 2-8°C for one week or (in aliquots) at -20°C to -80°C for longer. Avoid repeated freezing and thawing. Stability: Shelf life: one year from despatch. RefSeq: NP_001138638 Locus ID: 10196 UniProt ID: Q8WUV3 Cytogenetics: 11p15.1 Synonyms: HRMT1L3 Summary: This gene belongs to the protein arginine methyltransferase (PRMT) family. The encoded enzyme catalyzes the methylation of guanidino nitrogens of arginyl residues of proteins. The enzyme acts on 40S ribosomal protein S2 (rpS2), which is its major in-vivo substrate, and is involved in the proper maturation of the 80S ribosome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013] This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 PRMT3 (1-531, His-tag) Human Protein – AR51778PU-N Protein Families: Druggable Genome Product images: This product is to be used for laboratory only.
    [Show full text]
  • Utilising Clinical Exome Sequencing in Patients with Rare Genetic Disease and Regions of Homozygosity Detected by SNP Microarray
    Utilising clinical exome sequencing in patients with rare genetic disease and regions of homozygosity detected by SNP microarray A thesis submitted to The University of Manchester for the degree of Doctor of Clinical Science In the faculty of Biology, Medicine and Health 2020 Lewis P Darnell School of Biological Sciences, Division of Cell Matrix Biology and Regenerative Medicine List of Contents Description Page Number Word count 7 List of figures 8 List of tables 9 List of abbreviations 10 Abstract 11 Declaration 12 Copyright statement 12 Acknowledgements 14 The author 15 1 Introduction 16 1.1 Introduction to Rare Genetic Disease 17 1.1.1 Rare Genetic Disorders 17 1.1.2 Diagnosing Rare Genetic Disorders 20 1.1.3 Consanguinity and Genetic Disease 22 1.2 Genetic Testing Methods 27 1.2.1 Microarray 27 1.2.2 DNA Sequencing 30 1.2.3 Whole Exome Sequencing 34 1.2.4 Clinical Exome Sequencing 38 1.2.5 Whole Genome Sequencing 41 1.2.6 Genetic Testing Summary 42 1.3 Variant Analysis 45 1.3.1 Variant Prioritisation 45 2 1.3.2 Variant Analysis 48 1.4 Genetic Testing for Rare Disease in the East Midlands 49 1.5 The Importance of this Research and Controversial Issues 53 1.6 Research Hypothesis 58 1.6.1 Research Question 58 1.6.2 Overarching Hypothesis 58 1.6.3 Specific Hypothesis 59 1.7 Detailed Project Aims 60 1.8 Evaluation of the Methodology Decision 62 1.9 Relevance to Research Area 64 1.10 Summary 65 2 Materials and Methods 67 2.1 Participants and Phenotypes 67 2.1.1 Participant Referral 67 2.1.2 Ethics and Consent 68 2.1.3 Participant Phenotypes,
    [Show full text]
  • A Tool for Clinical Management of Genetic Variants
    Wang et al. Genome Medicine (2015) 7:77 DOI 10.1186/s13073-015-0207-6 SOFTWARE Open Access ClinLabGeneticist: a tool for clinical management of genetic variants from whole exome sequencing in clinical genetic laboratories Jinlian Wang, Jun Liao, Jinglan Zhang, Wei-Yi Cheng, Jörg Hakenberg, Meng Ma, Bryn D. Webb, Rajasekar Ramasamudram-chakravarthi, Lisa Karger, Lakshmi Mehta, Ruth Kornreich, George A. Diaz, Shuyu Li, Lisa Edelmann* and Rong Chen* Abstract Routine clinical application of whole exome sequencing remains challenging due to difficulties in variant interpretation, large dataset management, and workflow integration. We describe a tool named ClinLabGeneticist to implement a workflow in clinical laboratories for management of variant assessment in genetic testing and disease diagnosis. We established an extensive variant annotation data source for the identification of pathogenic variants. A dashboard was deployed to aid a multi-step, hierarchical review process leading to final clinical decisions on genetic variant assessment. In addition, a central database was built to archive all of the genetic testing data, notes, and comments throughout the review process, variant validation data by Sanger sequencing as well as the final clinical reports for future reference. The entire workflow including data entry, distribution of work assignments, variant evaluation and review, selection of variants for validation, report generation, and communications between various personnel is integrated into a single data management platform. Three case studies are presented to illustrate the utility of ClinLabGeneticist. ClinLabGeneticist is freely available to academia at http://rongchenlab.org/software/clinlabgeneticist. Background effects, and testing of tumor biopsies to determine somatic Molecular genetic testing is playing an increasingly im- alterations for cancer classification, prognosis, and devel- portant role in medicine.
    [Show full text]
  • The Genetic Complexity of Prostate Cancer
    G C A T T A C G G C A T genes Review The Genetic Complexity of Prostate Cancer Eva Compérat 1,2,3,*, Gabriel Wasinger 3 , André Oszwald 3 , Renate Kain 3 , Geraldine Cancel-Tassin 1 and Olivier Cussenot 1,4 1 CeRePP/GRC5 Predictive Onco-Urology, Sorbonne University, 75020 Paris, France; [email protected] (G.C.-T.); [email protected] (O.C.) 2 Department of Pathology, Hôpital Tenon, Sorbonne University, 75020 Paris, France 3 Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria; [email protected] (G.W.); [email protected] (A.O.); [email protected] (R.K.) 4 Department of Urology, Hôpital Tenon, Sorbonne University, 75020 Paris, France * Correspondence: [email protected]; Tel.: +33-658246024 Received: 28 September 2020; Accepted: 23 November 2020; Published: 25 November 2020 Abstract: Prostate cancer (PCa) is a major concern in public health, with many genetically distinct subsets. Genomic alterations in PCa are extraordinarily complex, and both germline and somatic mutations are of great importance in the development of this tumor. The aim of this review is to provide an overview of genetic changes that can occur in the development of PCa and their role in potential therapeutic approaches. Various pathways and mechanisms proposed to play major roles in PCa are described in detail to provide an overview of current knowledge. Keywords: prostate cancer; germline mutations; somatic mutations; PTEN; TMPRSS2; ERG; androgen receptors 1. Introduction Prostate cancer (PCa) is a major concern in public health, with more than 1.1 million cases worldwide detected every year [1].
    [Show full text]
  • The Protein Arginine Methyltransferase PRMT5 Regulates Proliferation
    The Protein Arginine Methyltransferase PRMT5 Regulates Proliferation and the Expression of MITF and p27Kip1 in Human Melanoma DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University by Courtney Nicholas Graduate Program in Molecular, Cellular, and Developmental Biology The Ohio State University 2012 Dissertation Committee: Gregory B. Lesinski, PhD, Advisor Jiayuh Lin, PhD Amanda E. Toland, PhD Susheela Tridandapani, PhD Copyright by Courtney Nicholas 2012 Abstract The protein arginine methyltransferase-5 (PRMT5) enzyme is a Type II arginine methyltransferase that can regulate a variety of cellular functions. We hypothesized that PRMT5 plays a unique role in regulating the growth of human melanoma cells. Immunohistochemical analysis indicated significant upregulation of PRMT5 in human melanocytic nevi (88% of specimens positive for PRMT5), malignant melanomas (90% positive) and metastatic melanomas (88% positive) as compared to normal epidermis (5% of specimens positive for PRMT5; p<0.001, Fisher’s exact test). Furthermore, nuclear PRMT5 was significantly decreased in metastatic melanomas as compared to primary cutaneous melanomas (p<0.001, Wilcoxon rank sum test). Human metastatic melanoma cell lines in culture expressed PRMT5 predominantly in the cytoplasm. PRMT5 was found to be associated with its enzymatic cofactor Mep50, but not associated with STAT3 or cyclin D1. However, histologic examination of tumor xenografts from athymic mice revealed a heterogeneous pattern of nuclear and cytoplasmic PRMT5 expression. siRNA-mediated depletion of PRMT5 inhibited proliferation in a subset of melanoma cell lines, while it accelerated the growth of others. Loss of PRMT5 also led to reduced expression of MITF (microphthalmia-associated transcription factor), a melanocyte-lineage specific oncogene, and increased expression of the cell cycle regulator p27Kip1.
    [Show full text]
  • Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
    Stem Cell Rev and Rep DOI 10.1007/s12015-016-9662-8 Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications Behnam Ahmadian Baghbaderani 1 & Adhikarla Syama2 & Renuka Sivapatham3 & Ying Pei4 & Odity Mukherjee2 & Thomas Fellner1 & Xianmin Zeng3,4 & Mahendra S. Rao5,6 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract We have recently described manufacturing of hu- help determine which set of tests will be most useful in mon- man induced pluripotent stem cells (iPSC) master cell banks itoring the cells and establishing criteria for discarding a line. (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Keywords Induced pluripotent stem cells . Embryonic stem Reports, 5(4), 647–659, 2015). In this manuscript, we de- cells . Manufacturing . cGMP . Consent . Markers scribe the detailed characterization of the two iPSC clones generated using this process, including whole genome se- quencing (WGS), microarray, and comparative genomic hy- Introduction bridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibra- Induced pluripotent stem cells (iPSCs) are akin to embryonic tion material and with a reporter subclone and lines made by a stem cells (ESC) [2] in their developmental potential, but dif- similar process from different donors. We believe that iPSCs fer from ESC in the starting cell used and the requirement of a are likely to be used to make multiple clinical products. We set of proteins to induce pluripotency [3]. Although function- further believe that the lines used as input material will be used ally identical, iPSCs may differ from ESC in subtle ways, at different sites and, given their immortal status, will be used including in their epigenetic profile, exposure to the environ- for many years or even decades.
    [Show full text]